EQL Pharma (EQL) Stock Overview
Engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
EQL Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
EQL Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 54.50 |
| 52 Week High | SEK 98.60 |
| 52 Week Low | SEK 53.80 |
| Beta | 0.54 |
| 1 Month Change | -11.53% |
| 3 Month Change | -40.83% |
| 1 Year Change | -19.85% |
| 3 Year Change | 112.06% |
| 5 Year Change | 88.58% |
| Change since IPO | 839.66% |
Recent News & Updates
EQL Pharma AB (publ) (STO:EQL) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
Oct 08
Do EQL Pharma's (STO:EQL) Earnings Warrant Your Attention?
Sep 27Recent updates
EQL Pharma AB (publ) (STO:EQL) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
Oct 08Do EQL Pharma's (STO:EQL) Earnings Warrant Your Attention?
Sep 27Capital Allocation Trends At EQL Pharma (STO:EQL) Aren't Ideal
Sep 09EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality
May 16
Pipeline Launches And Global Expansion Will Drive Future Success
Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly
Mar 12EQL Pharma aiming for 19% Revenue Growth in 5 Years
Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare.The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested
Jan 27EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce
Dec 14Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?
Nov 27Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
Oct 29EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 22Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16
Shareholder Returns
| EQL | SE Healthcare | SE Market | |
|---|---|---|---|
| 7D | -7.8% | -6.9% | -2.3% |
| 1Y | -19.9% | 33.7% | 0.5% |
Return vs Industry: EQL underperformed the Swedish Healthcare industry which returned 34.7% over the past year.
Return vs Market: EQL underperformed the Swedish Market which returned 2.8% over the past year.
Price Volatility
| EQL volatility | |
|---|---|
| EQL Average Weekly Movement | 7.1% |
| Healthcare Industry Average Movement | 4.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.6% |
| 10% least volatile stocks in SE Market | 2.9% |
Stable Share Price: EQL has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: EQL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 20 | Axel Schorling | www.eqlpharma.com |
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
EQL Pharma AB (publ) Fundamentals Summary
| EQL fundamental statistics | |
|---|---|
| Market cap | SEK 1.61b |
| Earnings (TTM) | SEK 29.61m |
| Revenue (TTM) | SEK 399.07m |
Is EQL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EQL income statement (TTM) | |
|---|---|
| Revenue | SEK 399.07m |
| Cost of Revenue | SEK 236.26m |
| Gross Profit | SEK 162.81m |
| Other Expenses | SEK 133.20m |
| Earnings | SEK 29.61m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 03, 2026
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 40.80% |
| Net Profit Margin | 7.42% |
| Debt/Equity Ratio | 172.5% |
How did EQL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/06 09:15 |
| End of Day Share Price | 2025/11/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EQL Pharma AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | DNB Carnegie Commissioned Research |